Evidence map›Paper›PMID 33191320›Full record

ArticleInternal medicine (Tokyo, Japan)2021

A Multicenter Study of Docetaxel at a Dose of 100 mg/m

Taizo Hirata, Shinji Ozaki, Masahiro Tabata, Takayuki Iwamoto, Shiro Hinotsu, Akinobu Hamada, Takayuki Motoki, Tomohiro Nogami, Tadahiko Shien, Naruto Taira and 2 more

Open access · diamondAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Taizo HirataDepartment of Medical Oncology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Japan.
Shinji OzakiDepartment of Breast Surgery, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Japan.
Masahiro TabataDepartments of Allergy and Respiratory Medicine, Okayama University Hospital, Japan.
Takayuki IwamotoDepartments of Breast and Endocrine Surgery, Okayama University Hospital, Japan.
Shiro HinotsuDepartment of Biostatistics, Sapporo Medical University, Japan.
Akinobu HamadaDivision of Clinical Pharmacology & Translational Research, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Japan.
Takayuki MotokiDepartment of Surgery, Okayama Saiseikai General Hospital, Japan.
Tomohiro NogamiDepartment of Surgery, Tsuyama Chuo Hospital, Japan.
Tadahiko ShienDepartments of Breast and Endocrine Surgery, Okayama University Hospital, Japan.
Naruto TairaDepartments of Breast and Endocrine Surgery, Okayama University Hospital, Japan.
Junji MatsuokaDepartments of Breast and Endocrine Surgery, Okayama University Hospital, Japan.
Hiroyoshi DoiharaDepartments of Breast and Endocrine Surgery, Okayama University Hospital, Japan.
Okayama University Hospital · JPKure Medical Center · JPOkayama Saiseikai General Hospital · JPSapporo Medical University · JPTsuyama Chuo Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective This study examined the pharmacokinetics, safety and anti-tumor activity of docetaxel at a dose of 100 mg/m

Indexed as

Breast NeoplasmsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsDocetaxelDrug Administration ScheduleHumansJapanMiddle AgedNeoplasm Recurrence, LocalTaxoidsDocetaxelTaxoids100 mg/m2advanced or recurrent cancerdocetaxelJapanesephase I study

Identifiers

PMID33191320
PMCPMC8112988
OpenAlexW3100374033

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.